Based on the above findings, several consensus reports from major international bodies recommend SGLT2 inhibitors as the drug of choice after metformin in patients with T2DM and evidence of atherosclerotic cardiovascular disease, CKD or heart failure [81,100]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.